Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase‐2 and MMP‐9

Abstract

BACKGROUND The transcription factor avian erythroblastosis virus E26 (V‐Ets) oncogene homolog 1 (Ets‐1) is involved in tumor development and progression through the transcriptional regulation of several matrix‐degrading enzyme systems, including matrix metalloproteinases (MMPs). It has been demonstrated that the MMPs are expressed strongly in high‐grade meningiomas. To determine the biologic significance of Ets‐1 in the progression of benign meningiomas, the authors investigated the expressions of Ets‐1 and its target genes MMP‐2 and MMP‐9 in primary and recurrent, Grade 1 meningiomas. METHODS The expression levels of Ets‐1, MMP‐2, and MMP‐9 were examined by immunohistochemistry in 70 Grade 1 meningiomas, including 36 primary tumors without recurrence after 5 years of follow‐up and 17 pairs of primary tumors and subsequent recurrences. RESULTS The results demonstrated higher expression of Ets‐1, MMP‐2, and MMP‐9 proteins in meningiomas with subsequent recurrences compared with meningiomas from patients who had no recurrences (P < .001). In addition, Ets‐1 expression was correlated with the expression of both MMP‐2 and MMP‐9. CONCLUSIONS Ets‐1 may be involved in meningioma recurrence by up‐regulating MMP‐2 and MMP‐9. Increased expression of these genes in World Health Organization grade 1 meningiomas may serve as an indicator for a high risk of recurrence. Cancer 2006. © 2006 American Cancer Society.

Comparative gene expression profiling of ADAMs, MMPs, TIMPs, EMMPRIN, EGF-R and VEGFA in low grade meningioma

“…MMP2 was generally very highly or highly expressed. This finding is consistent with previous reports suggesting their association with the potential to invade, especially increased levels of MMP2 and MMP9 in Grade 1 meningiomas as prognostic or predictive factors of recurrence (16,32). Moreover, in another study, the prognostic value of MMP9 in the risk of recurrence of meningiomas was investigated by analysing its expression in a series of meningiomas of different histological type and grade.…”

Microarray gene expression profiling in meningiomas: Differential expression according to grade or histopathological subtype

“…This molecule has also been described as a biomarker associated with poor outcome in breast cancer (52). MMP9, a component of the extracellular matrix, has been shown to be upregulated in atypical and anaplastic meningiomas (18,53) and has been proposed as a potential target for therapy in meningiomas (54). In contrast, the expression of SPON2, which has been shown to be overexpressed in ovarian cancer (55), and the expression of AIM2 have not been previously reported in meningiomas.…”

MicroRNA-146aandEts-1gene polymorphisms in ocular Behçet's disease and Vogt–Koyanagi–Harada syndrome

“…Recent studies have demonstrated that single nucleotide polymorphisms (SNPs) located either in the pre-miRNAs or within miRNA binding sites are likely to affect the expression of the miRNA targets and, thus, may contribute to the susceptibility to diseases 16 17. V-Ets oncogene homologue 1 (Ets-1), the first member of the Ets oncogene family, has been identified in the avian erythroblastosis virus E26 and shown to contribute to tumour development and progression 18. Recently, Luo et al 13 identified that Ets-1 binds to the miR-146a promoter region and strongly affected miR-146a promoter activity in vitro.…”